Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Sarcoma

1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)

Date

18 Sep 2020

Session

Mini Oral - Sarcoma

Topics

Tumour Site

Bone Sarcomas

Presenters

Emanuela Palmerini

Citation

Annals of Oncology (2020) 31 (suppl_4): S914-S933. 10.1016/annonc/annonc288

Authors

E. Palmerini1, C. Meazza2, A. Tamburini3, G. Bisogno4, V. Ferraresi5, S. Asaftei6, G.M. Milano7, L. Coccoli8, C. Manzitti9, R. Luksch2, D.M. Donati10, M. Serra11, R. Bertulli12, M. Gambarotti13, C. Favre14, A. Longhi15, P.G. Casali16, P. Picci17, F. Fagioli6, S. Ferrari18

Author affiliations

  • 1 Department Of Experimental, Diagnostic And Specialty Medicine - Dimes, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 2 Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 3 Dai-dipartimento Di Oncoematologia Pediatrica E Cure Domiciliar, Azienda Ospedaliera Universitaria A. Meyer, 50139 - Florence/IT
  • 4 Dipartimento Di Pediatria, Clinica di Oncoematologia Pediatrica, 35128 - Padua/IT
  • 5 Divisione Di Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, 00144 - Rome/IT
  • 6 Department Of Public Health And Pediatrics, Ospedale Infantile Regina Margherita, 10138 - Turin/IT
  • 7 Oncoematologia Pediatrica, L'Ospedale Pediatrico Bambino Gesù, Rome/IT
  • 8 Oncoematologia Pediatrica, Azienda Ospedaliero Universitaria Pisana, 56121 - Pisa/IT
  • 9 Dipartimento Di Emato-oncologia Pediatrica, IRCCS Istituto G. Gaslini - Ospedale Pediatrico, 16147 - Genoa/IT
  • 10 Department Of Biomedical And Neuromotor Sciences, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 11 Laboratory Of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 12 Sc Oncologia Medica Dei Tumori Mesenchimali Dell'adulto E Tumori Rari, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 13 Dipartimento Delle Patologie Ortopediche-traumatologiche Specialistich, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 14 Dipartimento Di Oncoematologia Pediatrica, Azienda Ospedaliera Universitaria A. Meyer, 50139 - Florence/IT
  • 15 Musculoskeletal Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 16 Medical Oncology Unit 2, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 17 Na, I.S.G. Italian Sarcoma Group, 40068 - Bologna/IT
  • 18 Medical Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 - Bologna/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1625MO

Background

Overexpression of ABCB1/P-glycoprotein (Pgp) predicts poor outcome in retrospective osteosarcoma series. Two prospective trials with Pgp expression as stratification factor were activated in Italy and Spain.

Methods

Patients ≤ 40 years with extremity high-grade osteosarcoma were eligible. Pgp expression was centralized. Preoperatively, all patients received MAP (methotrexate, adriamycin, platinum). In case of Pgp overexpression (Pgp+), mifamurtide (2 mg/m2 twice/week for 3 months than weekly for 6 months) was added after surgery, with 4 consecutive cycles of ifosfamide 3 gr/m2/day, day 1-5 (HDIFO) in case of poor response (PR) to MAP. Patients without overexpression of Pgp (Pgp-) received MAP postoperatively, regardless the pathological response. From March 2013, an amendment increased high dose methotrexate (HDMTX) cumulative dose from 60 g/m2 (5 cycles) to 120 mg/m2 (10 cycles). In the same period, this regimen was adopted in an observational prospective study performed by the Spanish Sarcoma Group (GEIS) (NCT04383288).

Results

From June 2011 to March 2018, 291 ISG patients were screened and 279 were included: 110 were Pgp-, 154 were Pgp+, while in 15 patients Pgp expression was not evaluable. With a median follow-up of 58 months (range 1.2 – 102.2), the 3-year EFS and OS were 65.5% (95% CI 59.4-70.9) and 85.8% (95% CI 81-89.6), respectively, with improved survival after 10 HDMTX cycles (table). Table: 1625MO

n % 3-yrs EFS (95% CI)
Pgp° 0.0587
Negative (MAP) 110 59.9 (49.8-68.7)
Positive (mifamurtide+HDIFO if PR) 154 70.1 (62.1-76.8)
Necrosis <0.0001
Good response 116 80 (71.3-86.4)
Poor response 163 55.1 (47-62.5)
Amendment 0.009
Pre (5 HDMTX cycles) 74 57.6 (45.4–67.9)
Post (10 HDMTX cycles) 205 68.4% (61.4-74.5)

°not evaluable in 15 patients

Conclusions

In this prospective uncontrolled study, EFS compared favorably with all our previous series. With a limited number of HDMTX cycles, EFS was suboptimal, and significantly improved after an amendment increasing HDMTX cycles to 10. Pgp+ patients performed well in this study, in which they were added mifamurtide and HDIFO after a PR to MAP: a pre-planned merged analysis of this study with a twin GEIS observational series is ongoing.

Clinical trial identification

NCT01459484; Eudract: 2011-001659-36.

Editorial acknowledgement

Legal entity responsible for the study

Italian Sarcoma Group (ISG).

Funding

The Onlus Association “Il Pensatore - Matteo Amitrano”; Fondazione Carisbo Clinical and Translational Research Grant 2019.

Disclosure

E. Palmerini: Honoraria (institution), Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Eusa Pharma ; Advisory/Consultancy: Deciphera; Honoraria (self), Travel/Accommodation/Expenses: Eli Lilly; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses, Non-remunerated activity/ies: PharmaMar; Honoraria (self), Honoraria (institution): Amgen; Non-remunerated activity/ies: Bristol Mayer Squibb; Non-remunerated activity/ies: Pfizer. M. Gambarotti: Honoraria (self), Honoraria (institution): Amgen. P.G. Casali: Honoraria (self): Bayer; Honoraria (self): Deciphera; Honoraria (self): Eisai; Honoraria (self): Eli Lilly; Honoraria (self): Nektar Therapeutics ; Honoraria (self): Pfizer; Honoraria (institution): Advencen Laboratories; Honoraria (institution): Amgen Dompé; Honoraria (institution): AROG Phaermaceuticals; Honoraria (institution): Bayer; Honoraria (institution): Blueprint medicines; Honoraria (institution): Daiichi Sankyo; Honoraria (institution): Deciphera; Honoraria (institution): Eisai; Honoraria (institution): Eli Lilly; Honoraria (institution): Epizyme Inc; Honoraria (institution): Glaxo; Honoraria (institution): Karyopharm Pharmaceuticals; Honoraria (institution): Novartis; Honoraria (institution): Pfizer; Honoraria (institution): PharmaMar. P. Picci: Honoraria (self), Travel/Accommodation/Expenses: Takeda; Honoraria (self), Honoraria (institution): Amgen. S. Ferrari: Honoraria (self): Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.